Over 90% of pancreatic cancers are known to harbor activating KRAS mutations and the other 10% have oncogenic fusions, BRAF mutations, Receptor Tyrosine Kinase (RTK) mutations/amplifications, or AKT/mTOR activation [46]. This evidence concerns the gene AKT1 and familial pancreatic carcinoma.